Method for obtaining protective cream against frostbite

FIELD: cosmetic industry.

SUBSTANCE: it is necessary to carry out immobilization of native casein of goat milk at 50°C obtained as a result of flocculation onto methyl cellulose followed by introducing fucoidane hydrolyzate, silver nitrate and glycoproteins of mucus of animal origin at the ratio of components that provide the following ratios of cream's components, weight%: glycoproteins of mucus of animal origin 13.0-15.0; native casein of goat milk 30.0-35.0; methyl cellulose 30.0-35.0; silver nitrate 2.0-2.5; fucoidane hydrolyzate 15.0-22.5.

EFFECT: higher efficiency.

7 cl, 2 ex, 1 tbl

 

The invention relates to the cosmetic industry and is designed to produce protective cream from frostbite.

A method of obtaining protective care cream (patent RU 2150935 C1 22.06.1999), which uses the whey proteins. Disadvantages are the complexity of the process, using some expensive components.

Closest to the proposed to the technical essence and the achieved positive effect is the way the medical protective care cream (patent RU 2253433 C2 17.12.2002), which contains substances that increase the exchange-reactive function of the skin. The disadvantage is that the resulting system does not provide protection from frostbite.

The purpose of the invention is to develop a method of producing a protective cream from frostbite, which gives the effect of cover anti-freeze with the use of secondary material resources.

For this purpose, the proposed method of producing cream, providing immobilization of protein on macromolecular carrier, with the subsequent introduction of antimicrobial and antifreeze agents, as protein use native casein goat's milk, which is applied to the methylcellulose at a temperature of 50°With the ratio of 1÷1, as antimicrobial agent use nitrate ser is bro, as antifreeze agent use animal glycoproteins of mucus and as a wound healing agent is hydrolyzed fucoidan extracted from brown seaweed Fucus vesiculosus.

The method of producing cream is as follows.

Methylcellulose is brought into a warm water with a temperature of 50÷60°to get a 1-1 .5% solution. The mixture was incubated for 1.5-2 hours. Temperature due to the following limitations: at temperatures below 50°and above 60°With the process of gelation is longer.

The obtained colloidal gel methylcellulose contribute in pre-homogenized and heated for better separation of goat milk to a temperature of 40÷45°With, in the ratio of 1÷1 by weight, followed by a gradual cooling during 2-3 hours to a temperature of 10÷15°and a temperature control with a 10÷15°C for 8÷10 hours. When making a solution of methylcellulose in a smaller number is not complete precipitation of casein, with the increase of the mass fraction of the solution of methylcellulose output casein remains unchanged, and the flow of components increases. Separation of protein and polysaccharide at a temperature below 10°and above 15°is slower.

This method of concentration of casein is based on two physico-chemical phenomena: limited thermodynamic compatibility of proteins and poly is faridul in water, as well as a higher osmotic pressure of a solution of a polysaccharide in comparison with the osmotic pressure of a solution of protein. Mixing solutions of protein and polysaccharide in certain concentrations leads to the formation of two-phase systems: the lower phase - concentrate casein, top - polysaccharide phase. Through the interface is the transfer of water from the protein solution into the solution of the polysaccharide to establish the phase equilibrium, which determines the concentration of casein.

The bottom layer containing the casein is separated in a flow tank.

Native goat casein and 4-5%solution of methylcellulose contribute in a chemical reactor in a ratio of components casein:methylcellulose 1:1 at a temperature of 50°where there is a continuous mixing for 30 minutes. In the resulting mass is injected with silver nitrate in an amount of 2.0-2.5% and after 30 minutes in the same reactor contribute hydrolyzed fucoidan extracted from brown seaweed Fucus vesiculosus.

To obtain hydrolyzed fucoidan 10 g of finely ground seaweed Fucus vesiculosis is subjected to extraction system of extractants: 1 g potassium phosphate, 1.3 g of sodium pyrophosphate and 0.3 g of sodium hydroxide in 50 ml of water. The mixture is stirred for 3-4 hours at a temperature of 60°C. Pasty mass is diluted four-fold amount of water and filtered. UNOSAT ml of 2 M aqueous solution of calcium chloride. This fucoidan is transformed into a soluble calcium salt, and alginic acid remains in the form of insoluble calcium alginate, detachable centrifuge separation. The solution of the calcium salt of fucoidan deleteroute against distilled water for 24 hours

The mass is stirred and enter the treated animal glycoproteins of mucus in the number of 13-15%. To highlight the mucous membrane glycoproteins animals milled on the top through the bars of a diameter of 2-3 mm, spend it cleaning and remove glycoproteins by salting out with magnesium sulfate. For canning mucus using rectified spirit at the rate of 20% by weight of raw materials.

The finished product is a dense homogeneous mass of a light beige color, which is packaged in sterile packaging. The ratio of components in the compositions shown in table 1.

This method of producing cream is illustrated by examples of its manufacture.

Table 1
Composition of productThe ratio of components
12
Native casein goat milk30,035,0
The mucus glycoproteins of animal origin15,013,0
The methylcellulose30,035,0
Silver nitrate2,52,0
Hydrolyzed fucoidan22,515,0

Example 1. Native goat casein mixed with 4-5%solution of methyl cellulose in a ratio of components casein:methylcellulose 1:1 at a temperature of 50°C. the resulting mixture was stirred for 30 minutes. Next make silver nitrate in the amount of 2.5%, hydrolyzed fucoidan in the amount of 22.5%, isolated from the brown seaweed Fucus vesiculosus, and mucus glycoproteins of animal origin in the amount of 15%.

The cream is used in gel form, which advantages over other forms used for the same purpose, is that it is well applied to the skin, evenly and firmly held skin.

Example 2. Carried out as in example 1, except that the specified components are taken in the following ratio, wt.%:

Native goat casein35,0
The mucus glycoproteins of animal origin13,0
The methylcellulose35,0
Silver nitrate2,0
Hydrolyzed fucoidan is 15,0

Insertion of an IUD makes the tool plasticity, and by forming a film when applied to the skin increases with prolonging the action of the tool. Introduction casein provides education structure of the matrix and a high porous structure. Introduction to the formula of mucus glycoproteins of animal origin provides protection from frostbite. Hydrolyzed fucoidan speeds up the process of epithelialization small wounds on the skin, and silver nitrate acts as an antibacterial agent and provides stabilization of cream of microbial contamination.

Put the tool in a thin layer on the open skin area.

1. A method of obtaining a protective cream from frostbite, including the introduction of a mixture of components of animal origin, characterized in that conduct immobilization at 50°With native casein goat's milk, the resulting flocculation, methylcellulose, followed by the introduction of hydrolyzed fucoidan, nitric acid silver and mucus glycoproteins of animal origin when the ratio of components providing the following ratio of components, wt.%:

The mucus glycoproteins of animal origin13,0-15,0
Nati is hydrated casein goat milk 30,0-35,0
The methylcellulose30,0-35,0
Nitric acid silver2,0-2,5
Hydrolyzed fucoidan15,0-22,5.

2. The method according to claim 1, in which use 4-5%solution of methylcellulose, which is at 50°immobilized native casein goat's milk.

3. The method according to claim 1, characterized in that use casein allocated from skimmed goat's milk flocculation, using as a flocculant solution of methylcellulose 1-1,5 wt.% when the ratio of skim milk-solution of methylcellulose 1÷1.

4. The method according to claim 1, characterized in that the flocculation is performed by mixing the components, pre-heating milk to a temperature of 40-45°and subsequent gradual cooling over 2 hours to a temperature of 10-15°C.

5. The method according to claim 1, characterized in that the nitric acid silver as an antimicrobial agent, bring in the amount of 2.0 to 2.5 wt.%.

6. The method according to claim 1, characterized in that used as a wound healing agent hydrolyzed fucoidan administered in the amount of 15.0-22.5 wt.%.

7. The method according to claim 1, characterized in that as a protective agent from frostbite enter the mucus glycoproteins of animal origin in the amount of 13-15 wt.%.

8. The method according to claim 1, characterized in that the mucous membrane of the MEA is escaut on the top through the lattice, a diameter of 2-3 mm, spend it cleaning and remove glycoproteins by salting out magnesium sulfate.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves carrying out immobilization of protein on methylcellulose used as a high-molecular compound and modification of its surface. Goat native milk casein prepared by flocculation is immobilized on its surface at temperature 50°C. Then silver nitrate and fucoidan are added in the ratio of components providing the following ratio of components in the agent, wt.-%: goat native casein, 40-45; methylcellulose, 40-45; silver nitrate, 0.5-2.5, and fucoidan, 9.5-17.5. Invention provides expanding antibacterial and wound-healing agents.

EFFECT: improved preparing method of agent.

7 cl, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves collecting blood plasma enriched in blood platelets, incubating it with heparin during 18-24 h at +4°-6°C, centrifuging it at 3500-4000 rpm at +4°-6°C and suspending the obtained precipitate in 50-70 ml of 7-7.5% sodium hydrocarbonate solution. The produced output product is frozen at -40-42°C and stored under these conditions.

EFFECT: high quality of preparation applicable for treating trophic ulcers, decubitus ulcers and other skin injury cases.

2 cl

FIELD: medicine.

SUBSTANCE: method involves formation of cylinder consisting of carbonic acid "snow" with diameter 1.0 cm, not above, and applications by wound defect perimeter on border with health tissue are carried out. The exposition time is 5 s, not above. Cryoapplications are repeated in 7-10 days if necessary. Method provides reducing period for epithelium formation, to improve conditions for microcirculation and provide formation of normotrophic scars. Invention can be used in treatment of chronic wounds.

EFFECT: improved method of treatment.

3 tbl, 1 ex

FIELD: medicine, combustiology.

SUBSTANCE: invention relates to a method involving the complex antibacterial treatment of burn generalized infection using topical and parenteral effect with antiseptics and antibiotic in patients suffering from deep surface burns. Solution "Butol" is applied on wound at 1-3 days as water-drying dressing. For the following 4-10 days in each other day ointment "Butolol" is applied on wound and ointment "Butolan" is applied in the following period in surface burns up to complete epithelization and in deep burns after surgery - necrectomy and in preparing wounds for autodermoplastic. Ceftriaxone is administrated in the dose 2 g per a day simultaneously with the topical treatment from 1-st to 12-th day and galavite is administrated by intramuscular route in the dose 200 mg in the first day and in the dose 100 mg from the 2-d to 12-th day per 24 h. Method provides enhancing effectiveness of treatment of burn generalized infection and to reduce hospitalization period of patients.

EFFECT: improved method of treatment.

2 ex

FIELD: chemical-pharmaceutical industry, medicine.

SUBSTANCE: invention relates to a pharmaceutical preparation comprising a lipophilic phase in the amount 1-10% by mass, mixture of a surface-active substance and an accessory surface-active substance wherein a surface-active substance is chosen from polyoxyethylene glycerol esters and fatty acids and polyoxyethylene sorbitan esters and fatty acids, and an accessory surface-active substance is chosen from poloxamers, block-copolymers of polyoxyethylene and polyoxypropylene in the amount 1-50% by mass, hydrophilic phase in the amount 40-80% by mass, and ciclosporin or its derivatives as an active component in the concentration 0.1-20% by mass. Proposed pharmaceutical preparation is made in colloidal formulation for topical using and designated for treatment and prophylaxis of skin pathological alterations, and/or skin adventitious, and/or mucous envelopes including mucous envelopes in digestive tract, urogenital ways and bronchial system, and/or conjunctives.

EFFECT: valuable medicinal properties of pharmaceutical preparation.

17 cl, 5 tbl, 11 dwg

FIELD: medicine.

SUBSTANCE: method involves administering autolymphocyte fraction with stem cells and applying it to ulcer surface as injections. Then, newly separated fraction is applied as injection or application on ulcer surface with 7-8 days long pauses. The injections are done beginning from points arranged along ulcer perimeter and then over its surface in chessboard order. When administering the fraction as application, it is spread allover the ulcer surface.

EFFECT: enhanced effectiveness of treatment; excluded fraction and stem cells rejection.

2 cl

FIELD: medicine.

SUBSTANCE: method involves applying a gauze napkin on wound impregnated with ointment of the following composition, mas. p. p.: ecdysterone, 0.001-0.01 g; pot-marigold flowers 70% alcoholic tincture (1:10), 10.0 g; Saint-John's-wort perforated herb 40% alcoholic tincture (1:10), 10.0 g; polyethylene glycol (PEG)-1500, 50.0 g, and PEG-400, 30.0 g. Method provides stimulating tissues reparation, decreasing inflammation and analgesic effect. Invention can be used in treatment of suppurative wounds.

EFFECT: improved method of treatment.

3 ex

FIELD: medicine, cosmetics.

SUBSTANCE: invention proposes a medicinal agent for external using containing the following components: water, polymeric gel-forming composition and fresh donor or slaughter blood of velvet antlers deer in the following ratio of components, wt.-%: rare-cross-linked polymer of acrylic acid or polyvinylpyrrolidone as a gel-forming agent, 1-6; carbomer, 2-7; stabilizing agent, 0.001-0.2; softening agent (glycerol or polyethylene glycol, or propylene glycol), 0.1-30; ethanolamine, up to pH = 6-8; fresh donor or slaughter blood of velvet antlers deer, 0.1-20, and water, the balance. Method for preparing a medicinal agent for external using is based on preparing rare-cross-linked polymer aqueous solution in the ratio water/polymeric gel-forming agent = from 5:1 to 100:1, its mixing with fresh donor or slaughter blood of velvet antlers deer in the ratio = from 1:10 to 10:1 followed by addition of stabilizing and softening agents to prepared solution in the amount from 0.005 to 0.2 wt.-% and from 0.1 to 30 wt.-%, respectively. Prepared solution is stirred and neutralizing agent aqueous solution is added in the amount providing slightly alkaline medium in the final solution. Invention provides simplifying technology providing preparing a highly effective medicinal agent for external using, increasing fitness time up to 2 years being without detriment of its curative properties and reducing consumption for its producing.

EFFECT: improved preparing method, valuable medicinal properties of agent.

9 cl

FIELD: chemistry of peptides, medicine, pharmacology.

SUBSTANCE: invention relates to using the combination of bioactive regions SYSMEHFRWGKPV and YGGFM in pro-opiomelanocortine in manufacturing a medicine used in treatment of inflammatory, degenerative and autoimmune diseases, traumas, infections and burns. Also, invention relates to using polypeptide chosen from group: YGGFMSYSMEHFRWGKPVYGGEM, YGGFMSYSMEHFRWGKPV, SYSMEHFRWGKPVYGGFM and compositions eliciting cytoprotective properties. Invention provides enhancing in peptides effect.

EFFECT: valuable medicinal properties of peptides.

9 cl, 1 tbl, 1 dwg

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes hydrophilic and hydrophobic compositions used in treatment of infectious or viral diseases and a method for treatment. Hydrophilic composition comprises polynitro-compound of the formula: R-(NO2)n wherein n ≥ 2, dimethylsulfoxide and ethyl alcohol wherein the composition comprises dinitrotoluene and/or tetranitrotoluene, and pentanitrotoluene or mixture of at least one of them with trinitrotoluene as polynitro-compound of the formula R-(NO2)n. Hydrophobic composition comprises polynitro-compound of the formula: R-(NO2)n wherein n ≥ 2 and vegetable and/or animal fat wherein dinitrotoluene and/or tetranitrotoluene, and/or pentanitrotoluene or mixture of at least one of them with trinitrotoluene is used as polynitro-compound of the formula R-(NO2)n. Proposed compositions relate to lipotropic substances that are able to penetrate into tissues rapidly and blood and contact with pathogenic microflora actively.

EFFECT: valuable medicinal properties of compositions.

4 cl, 2 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out immobilization of protein on methylcellulose used as a high-molecular compound and modification of its surface. Goat native milk casein prepared by flocculation is immobilized on its surface at temperature 50°C. Then silver nitrate and fucoidan are added in the ratio of components providing the following ratio of components in the agent, wt.-%: goat native casein, 40-45; methylcellulose, 40-45; silver nitrate, 0.5-2.5, and fucoidan, 9.5-17.5. Invention provides expanding antibacterial and wound-healing agents.

EFFECT: improved preparing method of agent.

7 cl, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: the suggested transdermal therapeutic system (TTS) includes adhesive matrix that contains biologically active substance - rotigotin. The adhesive matrix contains thermofusible contact glue, the latter consists of contact glue, the mixture of different contact glues or contact glue with a plastifier and at 160°C is of dynamic viscosity being 100 Pa·sec, not more. TTS has been obtained due to hot fusion technique: before stratifying the adhesive matrix its components should be fused and homogenized without usage of solvents at 70-200°C. According to the present innovation TTS has got high degree of filling with rotigotin which is released out of thermofusible matrices constantly and at therapeutically desirable rate. Rotigotin in case of carrying out the technique of hot fusion keeps its stability at heating up to 160°C. There is no necessity in applying, removing, regenerating or burning up organic solvents and providing corresponding safety measures during TTS manufacturing.

EFFECT: higher efficiency.

24 cl, 10 dwg, 10 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: the suggested compositions include taxol as a factor to inhibit the development of blood vessels and a pharmaceutically acceptable carrier. Also, it has been described the method of embolization of blood vessel dealing with the supply of therapeutically efficient quantity of the above-mentioned composition into the vessel mentioned. According to the innovation in question these compositions are nontoxic, thrombogenic, they don't change their form or physical properties during storage period before their application, they reveal no clotting signs at formation of large-sized particles in solution and after injection, they lead to slow release of the factor that inhibits the development of blood vessels.

EFFECT: higher efficiency.

18 cl, 22 dwg, 19 ex, 3 tbl

FIELD: chemical-pharmaceutical industry.

SUBSTANCE: the present innovation refers to the area of medicinal preparations, to new thyxotropic butyric carrier, in particular, that contains about 0.2-5 weight% colloid silicon dioxide and about 0.2-5 weight% hydrophilic polymer in edible oil. Interaction between hydrophilic polymer and colloid silicon dioxide in case of their application in the above-mentioned range of concentrations enables to keep low concentration of the last component, but, moreover, provides the chance to obtain solution at sufficient thyxotropy and low viscosity in case of shift. Moreover, the present innovation deals with capsules filled with a thyxotropic carrier and a pharmaceutically active substance.

EFFECT: higher efficiency.

17 cl, 11 ex, 1 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes a sustained-release composition comprising the following components: (1) a derivative of LH-RH of the formula: 5-oxo-Pro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C2H5 or its acetate, or its salt taken in the amount from 14% (mas./mas.) to about 24% (mas./mas.) of the total composition mass; (2) 3-hydroxy-2-naphthoic acid or its salt, and (3) polymer of lactic acid or its salt with average-mass molecular mass from 15000 to 50000 Da wherein the content of polymers with molecular mass from 5000 Da or below is 5% by mass or below and wherein the molar ratio of 3-hydroxy-2-naphthoic acid or its salt to derivative of LH-RH or its salt = from 3:4 to 4:3. Also, invention describes a method for preparing the composition and a medicinal preparation comprising the regulated composition. Proposed composition provides the constant release rate for the prolonged time based on inhibition of the parent intensive release of a pharmaceutically active compound.

EFFECT: improved and valuable properties of composition.

17 cl, 8 tbl, 22 ex

FIELD: medicine, cosmetics.

SUBSTANCE: invention proposes a medicinal agent for external using containing the following components: water, polymeric gel-forming composition and fresh donor or slaughter blood of velvet antlers deer in the following ratio of components, wt.-%: rare-cross-linked polymer of acrylic acid or polyvinylpyrrolidone as a gel-forming agent, 1-6; carbomer, 2-7; stabilizing agent, 0.001-0.2; softening agent (glycerol or polyethylene glycol, or propylene glycol), 0.1-30; ethanolamine, up to pH = 6-8; fresh donor or slaughter blood of velvet antlers deer, 0.1-20, and water, the balance. Method for preparing a medicinal agent for external using is based on preparing rare-cross-linked polymer aqueous solution in the ratio water/polymeric gel-forming agent = from 5:1 to 100:1, its mixing with fresh donor or slaughter blood of velvet antlers deer in the ratio = from 1:10 to 10:1 followed by addition of stabilizing and softening agents to prepared solution in the amount from 0.005 to 0.2 wt.-% and from 0.1 to 30 wt.-%, respectively. Prepared solution is stirred and neutralizing agent aqueous solution is added in the amount providing slightly alkaline medium in the final solution. Invention provides simplifying technology providing preparing a highly effective medicinal agent for external using, increasing fitness time up to 2 years being without detriment of its curative properties and reducing consumption for its producing.

EFFECT: improved preparing method, valuable medicinal properties of agent.

9 cl

FIELD: polymer materials.

SUBSTANCE: invention concerns amorphous light-sensitive cross-linked polymeric structure and provides structure including (i) amorphous cross-linked structure formed from matrix based on acrylate and/or methacrylate compound and cross-linking agent and (ii) photoreactive component capable of undergoing reversible photodimerization reaction. Cross-linked structures are characterized by good properties with shape-memory effect.

EFFECT: increased mechanical strength of material with desired property profile.

21 cl, 4 dwg, 2 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: method involves a) adding composition containing active substance, to organic polymer solution and dispersing in it; b) adding emulsion or dispersion produced at staged a) to external phase and dispersed in it, the external phase having temperature of 0 to 20°C at the moment of adding, external phase being like aqueous solution or oil phase containing emulsifying agent and/or protection colloid; c) removing organic solvent to subject emulsion or dispersion produced at stage b), to pressure action less than less than 1000 mbar or introducing inert gas into emulsion or dispersion produced at stage b). Micro particles produced in this way possess favorable properties. Active substance quantity released during flash stage, is insignificant, but total release volume is high. Active substance release lasts several weeks or months.

EFFECT: enhanced effectiveness of treatment; slow release of active substance.

25 cl, 8 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with stable peroral solid composition of ramosetron or its pharmaceutically acceptable salt. The composition includes one or several components chosen out of the groups including aliphatic carboxylic acid or its ester, hydroxycarboxylic acid or its ester, acidic amino acid, enolic acid, aromatic carboxylic compound or its ester and high-molecular substance that contains carboxylic group. Such an innovation refers to the method for stabilizing ramosetron composition. The suggested innovation provides stability of ramosetron composition under conditions of increased temperature and humidity, especially at low content of active component.

EFFECT: higher efficiency of application.

14 cl, 10 ex, 6 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes an orally administrated liquid composition used in treatment of respiratory diseases and comprising from 2% to 40% of guaifenesin and a filling agent comprising from 5% to 25% of polyoxyalkylene block-copolymer, from 30% to 90% of hydrophilic solvent, and from 5% to 45% of water. The composition shows high physical stability in delivery of the concentrated doses of pharmaceutically active component, in particular, the active component doesn't show precipitation from solution for the prolonged times. Also, the composition remains in a liquid form in the mouth cavity that provides the effect of the pharmaceutically active agent of the composition on large areas in the mouth cavity mucosa.

EFFECT: enhanced effectiveness and valuable medicinal properties of agent.

6 cl, 16 tbl, 1 dwg, 16 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out immobilization of protein on methylcellulose used as a high-molecular compound and modification of its surface. Goat native milk casein prepared by flocculation is immobilized on its surface at temperature 50°C. Then silver nitrate and fucoidan are added in the ratio of components providing the following ratio of components in the agent, wt.-%: goat native casein, 40-45; methylcellulose, 40-45; silver nitrate, 0.5-2.5, and fucoidan, 9.5-17.5. Invention provides expanding antibacterial and wound-healing agents.

EFFECT: improved preparing method of agent.

7 cl, 1 tbl, 3 ex

Up!